Table 1.
Patient characteristics of standard-dose group and over-dose group
| Characteristics | Standard-dose group (n = 146) | Over-dose group (n = 24) |
|---|---|---|
| Gender | ||
| Male | 70 (47.95%) | 14 (58.33%) |
| Female | 76 (52.05%) | 10 (41.67%) |
| Age | 43.30 ± 12.10 | 38.58 ± 14.01 |
| ECOG PS | ||
| 0 | 71 (48.63%) | 7 (29.17%) |
| 1 | 75 (51.37%) | 17 (70.83%) |
| Histological types | ||
| Undifferentiated sarcoma | 36 (24.66%) | 6 (25.00%) |
| Synovial sarcoma | 23 (15.75%) | 4 (16.67%) |
| Leiomyosarcoma | 20 (13.70%) | 3 (12.50%) |
| Fibrosarcoma | 16 (10.96%) | 3(10.34%) |
| Liposarcoma | 15 (10.27%) | 2 (8.33%) |
| Angiosarcoma | 14 (9.59%) | 6 (25.00%) |
| Epithelioid sarcoma | 7 (4.79%) | |
| MPNST | 7 (4.79%) | |
| Clear cell sarcoma | 3 (2.05%) | |
| Others | 5 (3.42%) | |
| Metastatic or locally unresectable | ||
| Locally unresectable | 20 (13.70%) | 7 (29.17%) |
| Metastatic | 120 (82.20%) | 17 (70.83%) |
| Both | 6 (4.11%) | 0 |
| Primary site | ||
| Extremities | 101 (69.18%) | 14 (58.33%) |
| Trunk | 45 (30.82%) | 10 (41.67%) |
| Metastatic site | ||
| Lung | 124 (84.93%) | 16 (66.67%) |
| Other | 22 (15.07%) | 8 (33.33%) |
| Mean cycles of doxorubicin chemotherapy | 5 | 11.5 |
Notes: Data are presented as numbers (percentages) or means ± standard deviations
Abbreviations: ECOG PS Eastern Cooperative Oncology Group performance status, MPNST malignant peripheral nerve sheath tumor